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The complexity of choosing a particular treatment for an 
individual patient while keeping her informed about the 
relevant options and considerations keeps increasing as 
personal genetic information becomes more commonly 
available. This is leading clinicians and patients to question 
their role in the decision-making process. For example, 
what  role  should  patients  take  in  choosing  between 
alternative  treatment  options,  in  particular  when  the 
benefits and risks of each option are not crystal clear? To 
what extent should clinicians share their own hesitations 
about the best treatment choice, exposing their patients 
to  the  incomplete  knowledge  about  each  alternative? 
How  should  clinicians  take  such  decisions  without 
exposing  patients  to  superfluous  stress  when  current 
knowledge  about  the  advantages  and  drawbacks  of 
available therapy options is far from complete?
These questions, and the doctor’s dilemma, have long 
been the topic of public discourse. Over 800 years ago, 
Maimonides,  a  prominent  Jewish  philosopher  and 
practicing  physician,  wrote  that  ‘the  risk  of  a  wrong 
decision  is  preferable  to  the  terror  of  indecision’. 
Although this remains as true as ever, should we not be 
asking  what  role  patients  have  in  taking  a  treatment 
decision - even when current knowledge is incomplete? 
Such questions seem to be more pertinent as we enter 
the  age  of  personal  genomes,  when  an  individual’s 
pharma  cogenomic data may affect their choice between 
treatment  options  [1-3].  Can  patients  comprehend 
complex diagnostic information and act on it when they 
face  a  choice  between  alternative  therapeutic  options, 
based on their personal genomic data? In other words, 
should  patients  be  made  aware  of  the  fine  details  of 
current  medical  knowledge,  including  the  gaps  in  it, 
when  crucial  treatment  decisions  have  to  be  made? 
Inevitably, some of those decisions may later turn out to 
have been the wrong ones for them.
A real-world example
Wendy  Lorizio  and  colleagues  [4]  have  examined  this 
charged  issue  in  a  real-world  personalized  medicine 
scenario by following the treatment choices of 235 breast 
cancer  patients  currently  taking  or  planning  to  take 
tamoxifen for prevention of cancer recurrence and who 
were offered the CYP2D6 genotyping test. Their study is 
a fine example of our current knowledge limitations: at 
the  time  of  conducting  their  CYP2D6  genotyping  and 
follow-up  patients  survey  (March  2008  to  May  2010), 
most  published  studies,  based  on  retrospective  data, 
indicated that individuals having a CYP2D6 poor meta  bo-
lizer genotype (predictive of complete lack of the enzyme 
activity) were less likely to benefit from tamoxifen for the 
prevention  of  breast  cancer  recurrence  [5,6].  However, 
more recent meta-analysis and studies cast doubt about 
the  relevance  of  CYP2D6  genotypes  for  breast  cancer 
recurrence  in  tamoxifen-treated  patients  [7,8].  Thus,  it 
could  well  be  that  a  similar  study  taking  place  today 
would find other results, namely that patients would be 
less  likely  to  change  from  tamoxifen  to  another  drug 
following genotyping. As long as no consensus has been 
reached  on  the  effect  of  CYP2D6  genotypes  on  the 
efficacy  of  tamoxifen  for  preventing  breast  cancer 
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© 2011 BioMed Central Ltdrecurrence, monitoring the serum level of endoxifen, its 
active metabolite, seems the most appropriate biomarker 
for  adjusting  tamoxifen  dosages  [9].  Including  this 
biomarker  as  a  decision  making  tool  in  breast  cancer 
therapy seems to be justified at our currently incomplete 
state of knowledge. Moreover, it will remain a valuable 
biomarker  once  endoxifen  itself,  currently  in  clinical 
trials, is eventually approved as a drug [10].
The study by Lorizio et al. [4] found that 46% (6 of 13) 
of the breast cancer patients prescribed tamoxifen and 
genotyped  as  poor  CYP2D6  metabolizers  elected  to 
change their medication to another drug within the follow-
ing  6  months.  This  crucial  treatment  decision,  while 
obviously  taken  along  with  their  attending  physicians, 
must  have  been  affected  by  their  participation  in  the 
informational session held by the researchers before the 
genetic testing, in which the results of studies examining 
the effects of CYP2D6 genotypes on breast cancer recur-
rence were presented. Notably, the authors [4] found that 
about half the patients had previous knowledge about the 
relevance of CYP2D6 genotypes for tamoxifen therapy, 
with the source of this knowledge being their nurses or 
clinicians,  the  medical  literature  or  the  general  media 
(internet,  TV  and  newspapers).  Yet  it  seems  that 
perform  ing the genotyping tests and learning about their 
results  in  a  medical  setting  affected  the  decision  on 
switching treatment.
Moving towards personalized medicine
This study [4] does not examine the extent to which the 
decision about changing the medication was driven by 
the  patients  or  their  clinicians.  The  genotyping  results 
were  transferred  to  patients  through  their  attending 
physicians,  who  did  not  receive  specific  recommen-
dations along with the laboratory results. It would have 
been of interest to also interview the clinicians and find 
out  about  their  role  and  considerations  in  taking  this 
decision; however, this would require a larger study, as in 
this one only 13 patients of the 235 who were genotyped 
were found to be CYPD6 poor metabolizers [4]. However, 
this study [4] illustrates that when genotyping relevant to 
drug response is carried out in a clinical setting along 
with  informing  patients  about  the  test  implications  in 
advance  of  the  testing,  a  decision  about  medication 
change followed for about half the patients whose test 
results indicated (at that time) that they were unlikely to 
benefit from tamoxifen.
This  study  conveys  important  insights  for  moving 
personalized medicine forward: offering patients pharma-
co  genetic  testing  in  the  clinical  setting  along  with  an 
educational session on the test relevance for their medi-
cation choices is an effective route for taking informed 
treatment  decisions.  The  lesson  is  that  personalized 
medicine  can  be  practiced  in  a  participatory  way.  The 
challenge  will  be  to  keep  medicine  participatory  and 
patients  fully  informed  when  medicine  and  personal 
genomes  meet  -  which  may  not  be  as  far  away  as  it 
seemed just a decade ago.
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